• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胎盘病理检查诊断的复发性子宫内膜非典型增生:病例报告。

Recurrent endometrial atypical hyperplasia diagnosed by pathological examination of the placenta from a live birth: a case report.

机构信息

Department of Pathology, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin NanLu Chengdu, Chengdu, 610041, China.

Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), West China Second Hospital, Ministry of Education, Sichuan University, Chengdu, 610044, China.

出版信息

BMC Pregnancy Childbirth. 2023 Sep 25;23(1):691. doi: 10.1186/s12884-023-05972-0.

DOI:10.1186/s12884-023-05972-0
PMID:37749522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10519068/
Abstract

BACKGROUND

Pregnancy complicated with endometrial atypical hyperplasia, which is often observed during early pregnancy, is extremely rare.

CASE PRESENTATION

The patient was a 30-year-old woman who had premature delivery at 30 weeks gestation, and endometrial atypical hyperplasia was discovered by placental examination.

CONCLUSIONS

For patients who undergo fertility-sparing treatment for endometrial atypical hyperplasia, the evaluation of the decidua via the placental pathological examination is particularly important. These examinations make a great clinical contribution to the early detection and diagnosis of endometrial atypical hyperplasia.

摘要

背景

妊娠合并子宫内膜非典型增生,常发生于早期妊娠,极为罕见。

病例报告

患者为 30 岁女性,孕 30 周早产,胎盘检查发现子宫内膜非典型增生。

结论

对于接受子宫内膜非典型增生保留生育功能治疗的患者,胎盘病理检查对蜕膜的评估尤为重要。这些检查对子宫内膜非典型增生的早期发现和诊断具有重要的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/bc89d16ea44c/12884_2023_5972_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/f98d52bfc53a/12884_2023_5972_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/cffa72c40eb8/12884_2023_5972_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/bc89d16ea44c/12884_2023_5972_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/f98d52bfc53a/12884_2023_5972_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/cffa72c40eb8/12884_2023_5972_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/593f/10519068/bc89d16ea44c/12884_2023_5972_Fig2_HTML.jpg

相似文献

1
Recurrent endometrial atypical hyperplasia diagnosed by pathological examination of the placenta from a live birth: a case report.胎盘病理检查诊断的复发性子宫内膜非典型增生:病例报告。
BMC Pregnancy Childbirth. 2023 Sep 25;23(1):691. doi: 10.1186/s12884-023-05972-0.
2
[Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].非典型子宫内膜增生或子宫内膜癌患者保留生育功能治疗后的妊娠结局分析
Zhonghua Fu Chan Ke Za Zhi. 2020 Dec 25;55(12):857-864. doi: 10.3760/cma.j.cn112141-20200613-00501.
3
National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.生殖年龄段子宫内膜癌或不典型增生女性的护理和生育结局的全国模式。
Am J Obstet Gynecol. 2019 Nov;221(5):474.e1-474.e11. doi: 10.1016/j.ajog.2019.05.029. Epub 2019 May 22.
4
[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].[孕激素保留生育功能治疗早期子宫内膜癌及子宫内膜重度不典型增生患者的妊娠率及妊娠相关因素]
Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22.
5
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.二甲双胍联合孕激素治疗非典型增生/子宫内膜上皮内瘤变或子宫内膜癌的生育保留治疗:对反应影响不大,活产率低。
Gynecol Oncol. 2020 May;157(2):348-356. doi: 10.1016/j.ygyno.2020.02.008. Epub 2020 Feb 19.
6
Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.图宾根大学妇女健康系患者队列中早期子宫内膜癌的生育力保护管理。
Arch Gynecol Obstet. 2021 Jul;304(1):215-221. doi: 10.1007/s00404-020-05905-8. Epub 2021 Feb 19.
7
The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.不同保留生育功能治疗方式及产科结局在早期子宫内膜癌和不典型子宫内膜增生患者中的应用:30 例病例系列及系统评价。
Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:139-147. doi: 10.1016/j.ejogrb.2021.06.007. Epub 2021 Jun 12.
8
Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.宫腔镜手术联合孕激素作为保留生育功能疗法治疗早期子宫内膜癌和不典型增生患者的疗效及妊娠结局。
Arch Gynecol Obstet. 2023 Feb;307(2):583-590. doi: 10.1007/s00404-022-06626-w. Epub 2022 Jun 8.
9
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.中国患者使用口服孕激素对复杂性不典型增生和低级别子宫内膜癌进行保留生育功能治疗时肿瘤学及生殖结局的预后因素
Gynecol Oncol. 2015 Dec;139(3):424-8. doi: 10.1016/j.ygyno.2015.09.078. Epub 2015 Sep 30.
10
Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.复发性非典型子宫内膜增生和子宫内膜癌患者保留生育力治疗后肿瘤学和产科结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1902-1907. doi: 10.1136/ijgc-2020-001570. Epub 2020 Oct 13.

本文引用的文献

1
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma.欧洲妇科肿瘤学会/欧洲人类生殖与胚胎学会/欧洲胃肠内镜学会子宫内膜癌患者保留生育功能治疗指南
Hum Reprod Open. 2023 Feb 6;2023(1):hoac057. doi: 10.1093/hropen/hoac057. eCollection 2023.
2
[Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].[分子分类在子宫内膜癌和非典型子宫内膜增生保留生育功能治疗中的意义]
Zhonghua Fu Chan Ke Za Zhi. 2022 Sep 25;57(9):692-700. doi: 10.3760/cma.j.cn112141-20220628-00419.
3
Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins.
林奇综合征患者子宫内膜癌和非典型子宫内膜增生的保留生育功能治疗:错配修复蛋白免疫组化后的分子诊断
Front Med (Lausanne). 2022 Aug 25;9:948509. doi: 10.3389/fmed.2022.948509. eCollection 2022.
4
Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.保留生育功能治疗早期子宫内膜癌或不典型增生的生殖和妊娠结局:系统评价和荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2022 Jun;273:90-97. doi: 10.1016/j.ejogrb.2022.04.019. Epub 2022 Apr 25.
5
Pathological examination of a placenta leading to the diagnosis of endometrial carcinoma: A case report.一例经胎盘病理检查确诊为子宫内膜癌的病例报告
Mol Clin Oncol. 2022 Jan;16(1):24. doi: 10.3892/mco.2021.2457. Epub 2021 Dec 1.
6
Improving response to progestin treatment of low-grade endometrial cancer.改善孕激素治疗低级别子宫内膜癌的反应。
Int J Gynecol Cancer. 2020 Nov;30(11):1811-1823. doi: 10.1136/ijgc-2020-001309. Epub 2020 May 6.
7
[Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].非典型子宫内膜增生和早期子宫内膜癌患者复发后保留生育功能再治疗的临床疗效及妊娠结局
Zhonghua Fu Chan Ke Za Zhi. 2020 Jan 25;55(1):21-28. doi: 10.3760/cma.j.issn.0529-567X.2020.01.005.
8
Guideline No. 390-Classification and Management of Endometrial Hyperplasia.第390号指南——子宫内膜增生的分类与管理
J Obstet Gynaecol Can. 2019 Dec;41(12):1789-1800. doi: 10.1016/j.jogc.2019.03.025.
9
Endometrial carcinoma in a gravid uterus: a case report and literature review.妊娠子宫内的子宫内膜癌:病例报告及文献复习。
BMC Pregnancy Childbirth. 2019 Nov 20;19(1):425. doi: 10.1186/s12884-019-2489-y.
10
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.一项关于促性腺激素释放激素激动剂联合芳香化酶抑制剂作为肥胖型子宫内膜癌患者保留生育功能治疗的初步研究。
J Gynecol Oncol. 2019 Jul;30(4):e61. doi: 10.3802/jgo.2019.30.e61. Epub 2019 Feb 26.